Good morning everyone and welcome to the Viatris Q4 and Full Year 2024 Earnings Call. All participants will be in the listen-only mode. Please also note, today's event is being recorded. At this time I'd like to turn the conference call over to Bill Szablewski, Head of Capital Markets. Sir, please go ahead.

Good morning everyone. Welcome to our Q4 2024 earnings call. With us today is our CEO Scott Smith; CFO, Doretta Mistras; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff. During today's call, we'll be making forward-looking statements on a number of matters, including our financial guidance for 2025 and various strategic initiatives. These statements are subject to risk and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures. When discussing 2024 actual or reported results, we will be making certain comparisons to 2023 actual or reported results on a divestiture adjusted operational basis, which excludes the impact of foreign currency rates and also excludes the proportionate results from the divestitures that closed in 2024 and 2023 from the 2023 period. When discussing our expectations for 2025, we will be making certain comparisons to 2024 actual or reported results on a divestiture adjusted operational basis, which excludes the impact of foreign currency rates and also excludes the proportionate results from the divestitures that closed in 2024 from the 2024 period. We may refer to those as changes on an operational basis. With that, I'll hand the call over to our CEO, Scott Smith.

Good morning, everyone. 2024 was an important year for Viatris across all three of our strategic pillars. We saw growth in our base business increasing our new product revenues to $582 million. We completed our planned divestitures to simplify and streamline our organization. We returned approximately $825 million in capital to shareholders through dividends and share repurchases. We retired approximately $3.7 billion of debt and achieved our long-term gross leverage target. And we expanded our innovative portfolio with three new products, Selatogrel, Cenerimod, and Sotagliflozin to help build our pipeline of the future. We finished 2024 with a full year revenue growth of 2% on a divestiture adjusted operational basis in line with our guidance. On a reported basis, we had total revenues of approximately $14.7 billion, adjusted EBIT of approximately $4.7 billion, and adjusted EPS of $2.65 per share. Free cash flow was approximately $2.6 billion, excluding divestiture-related taxes and transaction costs. All in all, a very good year. Before we dive into our 2025 priorities, I want to give you an update on the remediation efforts at our facility in Indore, India, and the estimated impact for this year. The FDA inspected the facility in June. Following the inspection, we immediately began implementing a comprehensive remediation plan to address the FDA feedback. The necessary corrective actions are well underway, including but not limited to related personnel actions. And we have engaged independent third-party subject matter experts to support our efforts. I assure you we take these matters very seriously, as well as our commitment to quality across our entire network. We recently traveled to Indore to review the progress. I can tell you, we are more than halfway through our efforts. We expect to be completed in a few months, at which time we anticipate asking the FDA to conduct a re-inspection of the facility. We received a warning letter and import alert from the FDA at the end of December. The import alert affects 11 actively distributed products in the US, including lenalidomide. The FDA made exceptions subject to certain conditions for four products based on shortage concerns. We recently finished interactions with the FDA about potential additional product exceptions, and we do not expect any additional exceptions will be granted at this time. While product continues to be shipped from the facility to markets outside the U.S., we currently anticipate some impact on other markets, including parts of our ARV business in emerging markets, and to select generic products in Europe. We currently estimate the negative impact on 2025 total revenues to be approximately $500 million and on 2025 adjusted EBITDA to be approximately $385 million. To meet the needs of the patients we serve, we are working closely with our customers to mitigate any supply disruptions, including potential site transfers and third-party arrangements. Turning our attention to our 2025 priorities, we are very focused on continuing to drive our base business with strong execution across commercial markets, and we are expecting several notable new product launches this year. From a pipeline perspective, we have 10 unique molecules in Phase 3 clinical development across our portfolio, and we are expecting six Phase 3 readouts this year, including from Meloxicam, which is being developed as a potential opioid-sparing treatment in acute pain. In addition, we expect to achieve several important late-stage development milestones for our three innovative assets, selatogrel, cenerimod, and SOTA. To preserve the ongoing continuity of the development programs for selatogrel and cenerimod, we have updated certain terms of our original global research and development collaboration with Idorsia. Under the updated terms, we will receive the rights to additional territories for cenerimod, including important markets in Asia, a reduction in certain contingent milestone payments, which will help improve the long-term economics of these assets, and certain other considerations in exchange for assuming a portion of Idorsia's remaining development cost obligation. We continue to be excited by the promise of these two assets, and we will take full control over the development to help ensure development timelines remain on track. From a capital allocation perspective, we said that we expect our approach to be equally balanced between capital return and business investment over the next three to five years. In any given year, we may prioritize one over the other. In 2025, we are prioritizing returning capital to shareholders. We will continue to support our dividend and are targeting at least $500 million to $650 million in share repurchases this year. As we progress through the year, we expect to have additional flexibility, and as a reminder, we still have $1.5 billion in share repurchase authorization available to us. From a business development perspective, we will target accretive regional opportunities that leverage our unique commercial and R&D infrastructure and capabilities. Finally, we've begun an enterprise-wide initiative to review our global infrastructure and identify additional cost savings. We expect this program to deliver OpEx savings in 2026 and beyond. Later this year, we'll hold an Investor Day to talk about our long-term outlook, how we are advancing our base and innovative pipelines, and the progress we are making on our enterprise-wide review. Overall, I'm proud of what we accomplished in 2024, and I'm very confident in our future. We have our arms around the situation at Indore. In 2025, we have a significant opportunity to drive our base business, execute on our pipeline, return capital to shareholders, and position ourselves for growth in 2026 and beyond. Now I'll turn it over to Philippe to share an update on how we are advancing our pipeline.

Thank you, Scott. Our base business pipeline continues to be highly diversified across core generics, complex generics, and novel products. This robust and deep pipeline representing approximately 100 plus submissions annually is the backbone of our ability to deliver more than $450 million in new product revenues for each of the last five years. We made great progress in 2024, delivering $582 million in new product revenues, setting us up very nicely to hit our target range of $450 million to $550 million in 2025. This is a particularly important year from an R&D and scientific execution perspective, as we expect to receive approvals on a number of complex injectables that we have been steadily and strategically developing. These include Iron Sucrose, Octreotide, and Liraglutide. Glucagon was approved last year and is actively being launched. These are difficult to develop and difficult to manufacture medicines. And we are proud of the scientific and development expertise we have built in this area. We plan to continue to leverage this differentiated platform as we further advance our base business pipeline. In parallel, we are getting these complex injectables to approval. We are also very focused on progressing our novel and life cycle management programs. We have a number of Phase 3 readouts anticipated in 2025. The most near-term opportunity is Effexor for Generalized Anxiety Disorder in Japan. We announced positive top-line results of our randomized double-blind placebo-controlled Phase 3 study last year and recently received positive results from the Phase 3 open-label long-term extension required for approval in Japan. We anticipate filing our submission in the first half of this year. Another key program is for Xulane Low Dose, which is a transdermal patch that is being developed to offer women a low dose estrogen combination birth control option. We expect our Phase 3 readout in the first half of this year. We received positive results from our first Meloxicam Phase 3 bunionectomy study and are feeling optimistic about our development program, as we await our second Phase 3 readout in herniorrhaphy, which is anticipated later this year. We believe that this novel, fast-acting oral formulation of Meloxicam has the potential to be an important opioid-sparing treatment option for patients with acute pain. Now moving to our innovative pipeline, beginning with eye care, we are continuing to advance our ophthalmology programs with these three key registrational readouts expected in 2025. We are on track to receive top-line data for MR-139 of Pimecrolimus, Phase 3 study for Blepharitis in the first half of this year. We also have recently completed enrollment for our Phase 3 study evaluating MR-141 for Presbyopia and expect to receive top-line results in the first half of this year. Additionally, our partner recently received fast-track designation from the FDA for their investigational new drug application for MR-142, which is being developed for the treatment of visual loss in low-light conditions associated with Keratorefractive Surgery. A substantial subset of these patients has night driving impairment for which there is no label treatment, thereby supporting the fast-track designation. The development of this asset is also progressing well, and we anticipate completing Phase 3 enrollment and receiving top-line results in the first half of this year. For selatogrel and cenerimod, we continue to be focused on increasing and accelerating trial enrollment for both SOS-AMI and OPUS. Recruitment for OPUS is well underway with plans to complete enrollment in the second half of this year. We continue to submit data from the Phase 2 care study for publication, and three abstracts have recently been accepted for presentation at two major congresses, LUPUS 2025 and PANLAR 2025. We are discovering the multifaceted immunomodulatory properties of cenerimod and subgroup analysis from the Phase 2 case study on quality of life and impact on fatigue. Regarding selatogrel, the SOS-AMI trial is progressing according to previously communicated timelines. We have scaled up trial recruitment and increased awareness of the study. We are continuing to build on our legacy in this space and actively engage key opinion leaders and the broader cardiovascular community at key medical meetings around the world. Moving to sotagliflozin. We are pleased with the recent publication in The Lancet Diabetes and Endocrinology. This data provides strong evidence of sotagliflozin's clinical benefit in reducing major adverse cardiovascular events, or MACE, in patients with type-two diabetes, CKD, and high cardiovascular risk. The findings show that sotagliflozin significantly and meaningfully reduces MACE versus placebo, demonstrating early and broad cardiovascular protection in this population. Sotagliflozin is the first SGLT inhibitor to show significant reduction in both MI and stroke, highlighting the potential role of SGLT1 inhibition in reducing ischemic events, an important distinction from selective SGLT2 inhibitors. We are now collaborating with our partner Lexicon to explore next steps, including a potential label expansion to increase patient access as we continue to remain on track for our regulatory submissions starting in 2025 in key ex-U.S. markets. We will be leveraging Idorsia that led to the FDA's approval and expect registration in these markets starting in 2026. To recap, our R&D strategy is grounded in being disciplined about executing our near-term programs while preparing for the future. We have a strong focus on advancing our base business and innovative pipelines across multiple fronts, with important complex generics approvals, Phase 3 data readouts, and key development milestones in our novel and innovative pipelines, all expected this year. And we are continuing to actively build our GLP-1 pipeline and supply chain, which we will share more information about at our upcoming Investor Day. With that, I’ll hand it over to Corinne.

Thank you, Philippe. I’d like to start by outlining our three commercial priorities in 2025. First is driving the best business. 2024 was a strong year. All commercial segments grew year-over-year operationally. We aim to continue this momentum with focused execution in every aspect of the business to maximize the potential of our broad, generic and brand portfolios. This means continued attention on delivering high customer service levels and leveraging our global healthcare gateway and regional capabilities and infrastructure to expand patient access. Our second priority is to execute our product launches. We’re expecting a number of new products coming this year, such as our complex injectables. In total, we are tracking more than 150 generic launches globally, and our aim is to ensure commercial success for each launch. The fundamentals of our base business are strong, and we are confident we will deliver the expected $450 million to $550 million in new product revenues. Our third priority is preparing the future business. We are building upon our strong commercial infrastructure by enhancing our innovative product commercialization capabilities and expertise across key markets, and we are developing global commercialization strategies for innovative and novel pipeline assets. Turning to our outlook for the year. As we heard from Scott, we are expecting an approximate $500 million revenue impact related to Indore, affecting mostly the U.S. and emerging markets. In 2025, we expect total revenues to decline approximately 1%. Now let’s dive into the geographic segments starting with developed markets. Europe is expected to grow year-over-year. I want to highlight some of the key positive drivers behind this anticipated performance. First, we expect new product launches in both our brand and generic portfolios, including carryover benefits from the atorvastatin combination and rivaroxaban. Then the continued performance of our thrombosis portfolio as well as key brands, like Creon and Brufen. And finally, we anticipate further volume growth in key markets including Italy and France and strong generic performance across our diverse portfolio. North America is expected to decline year-over-year, which is driven by the Indore impact and expected competition on certain generics including Xulane, Glatiramer Acetate and Prednisolone. Our focus is to continue to capitalize on the strength of our complex generics portfolio with a stable contribution of products like Wixela and Breyna, as well as continuing the growth trajectory of promoted brands like Yupelri. And we are actively planning for several new launches during the course of the year in the complex injectable space, including iron sucrose and ocreotide plus glucagon, which we are in the midst of launching. The emerging market segment is expected to grow year-over-year, primarily driven by further expansion of our cardiovascular portfolio in Latin America, as well as expansion in key markets such as Turkey, India, Korea, Brazil, and Emerging Asia, and volume growth on our overall base portfolio. Moving to JANZ, similar to 2024, this year we expect continuing impacts from government-driven price regulations in Japan and Australia, as well as from a change in Japan’s reimbursement of patent brands that accelerated generic conversion. While we are forecasting JANZ to decline in 2025, we continue to benefit from ongoing strong volume growth from key brands and the expansion of our generic business, including through ongoing business development efforts. Japan is a key market and we are well underway preparing for the future. We are building our commercialization plans around a number of innovative and novel assets such as Effexor for generalized anxiety disorder, Nefecon, cenerimod, selatogrel, and sotagliflozin. Lastly, in Greater China, we expect to deliver year-over-year growth in 2025 stemming from the continued patient demand for our portfolio of iconic brands addressing chronic diseases that are more and more prevalent in China’s growing aging population. Our significant presence and leading organization in China, as well as our commitment to patient access, allow us to meet expanding healthcare demands. In addition, we expect to deliver on our pipeline with new product launches of Dymista and Breyna in China. By continuing to maximize our well-established commercial presence across multiple channels, including e-commerce, retail, and private hospitals, we expect to be able to absorb the impacts from potential government-implemented healthcare policy regulations. Overall, we are confident we will be able to deliver on our 2025 commitments through driving the base business and executing our new product launches, while preparing for successful future innovative launches. With that, I’ll turn the call to Doretta.

Thank you, Corinne. Building on the team’s comments around our operational performance, I’ll briefly highlight full year and fourth quarter results. As a reminder, my commentary on our financial performance will be on a divestiture adjusted operational basis. We reported 2024 total revenues of $14.7 billion which was up 2% year-over-year. This reflects growth across all segments and new product revenues of $582 million, which was at the high end of our increased range. Adjusted EBITDA was $4.7 billion, which benefited from adjusted gross margins of 58%, also at the high end of our range driven by strong brands and complex generics performance. As it specifically relates to the fourth quarter, total revenues of $3.5 billion were in line with our expectations and grew 1%. We saw continued momentum in growth across China, developed markets, and emerging markets. Our global generics business grew 2%, driven by new product launches and complex products. Gross margins were in line with expectations and moderated in the fourth quarter due to expected segment and product mix. We had a strong quarter of free cash flow totaling $685 million, excluding the impact from divestiture costs and taxes. Our free cash flow and proceeds from the divestitures were used to pay down approximately $1.4 billion in debt, which enabled us to achieve our gross leverage target ending the year at approximately 2.9 times. Now that we’ve closed the year, we are also providing an estimate of our 2024 results on an ex-divestiture basis. These estimates exclude the benefit from the divested businesses totaling approximately $490 million in total revenue and $255 million in adjusted EBITDA. Moving to our plan for 2025, I’ll summarize the key drivers to give you a full picture of the year ahead. Given the continued strength of the dollar, we have assumed an FX headwind of approximately 2% to 3% on total revenues. As a reminder, approximately 75% of our revenues occur outside of the U.S. Excluding the impact of Indore, we expect our operational revenues to benefit from continued momentum and strong fundamentals, primarily in Europe, China, and emerging markets. These trends give us confidence in the continued strength of our base business going forward. And as you heard from Scott, with respect to Indore, ongoing remediation has been an all-hands effort and is a top priority for our organization. We take the quality of our products very seriously and are making progress on the remediation plan, including the transfer of products across internal sites and with third parties where deemed possible and appropriate. Discussions with the FDA and our customers have been ongoing and have evolved to a point where we now have clarity on the products in scope and the anticipated associated financial impact, which we have included in our guidance. We estimate an impact of approximately $500 million to 2025 total revenue and $385 million to adjusted EBITDA. This includes estimated penalties and supply disruptions of approximately $100 million which we believe are mostly short-term in nature. Lenalidomide, which after discussions with the FDA was not granted an exception, is the largest product impacted and represents approximately 40% of the total revenue impact and 50% of the total adjusted EBITDA impact given its margin profile. Also, based upon the existing settlement agreements with generic manufacturers, we expect this product will face significant additional generic competition in early 2026. In Europe, we expect limited impact to select generic products. We believe this impact to be short-term and expect to recapture some of this volume in the future. In emerging markets, we anticipate our lower margin ARB business to experience certain disruptions over the short-term and we estimate an impact on total revenue of approximately $125 million. Moving to the drivers of gross margins and our adjusted EBITDA and EPS guidance. We expect gross margins to be impacted by Indore, normal base business price erosion, and an increase in some product supply costs. Partially offsetting this impact is the expected benefit from segment mix. As it relates to our outlook for SG&A and R&D, we are taking a disciplined approach to managing our expenses and allocation of resources. Total operating expenditures are expected to decline, as we work to optimize the portfolio and reduce stranded costs associated with the divestitures. Our guidance assumes a reduction of approximately $150 million, predominantly benefiting SG&A. And with respect to Idorsia, as Scott mentioned, we have amended the collaboration agreement. As a result, we expect to incur an incremental R&D expense of approximately $100 million in 2025. In exchange, we have received a $250 million reduction in contingent milestones, of which $200 million is from future development milestones. We have also gained additional territory rights for cenerimod. We expect our effective tax rate to increase by 150 basis points in 2025, due to anticipated impacts from Pillar 2. A few points on our expectations for free cash flow and cash available for deployment in 2025. We expect strong free cash flow generation of approximately $2 billion, which takes into account Indore remediation and foreign exchange totaling approximately $300 million. Net of taxes and transaction costs associated with the divestitures, we estimate that we’ll have approximately $1.7 billion available for deployment throughout the year. Consistent with our stated strategy, we continue to prioritize capital return in 2025 with a focus on share repurchases. As such, we expect to repurchase between $500 million and $650 million throughout the year, preserving flexibility to the upside. With the approved annual dividend policy of $0.48 per share, we expect to return over $1 billion of capital to shareholders, nearly 70% of our available capital. Now a few comments regarding phasing of our guidance. Total revenue is expected to be higher in the second half, driven by the back weighted launch of new products and normal product seasonality. We expect operating expenses to be evenly phased between the first half and second half. Taking into account phasing of revenue and margin, we expect adjusted EBITDA and adjusted EPS to also be more heavily weighted towards the second half. And as we think about the sequential quarterly roll forward, we expect the first quarter levels to step down from the fourth quarter, attributed to lower net sales from Indore related products and volume and seasonal impacts in Europe. Finally, we will continue to be disciplined with our financial policy and remain in a very strong position, given the breadth and diversity of our global portfolio, strong base business fundamentals, expected significant free cash flow generation, and efficient low coupon fixed rate capital structure. Looking ahead, we have laid out a clear and transparent plan for this year and I have confidence that our strong foundation will position us for long-term success. We look forward to updating you each quarter on our progress and being available for your questions. And with that, I’ll hand it back to the operator to begin the Q&A.

Ladies and gentlemen, we will now begin the question-and-answer session. And our first question today comes from David Amsellem from Piper Sandler. Please go ahead with your question.

Hey, thanks. Have a few. So, first I guess on the warning letter and the remediation. I guess any time there is a warning letter, you can’t help but wonder are there potential issues with quality control at other facilities? So I guess can you just talk about your level of confidence that this is something that is contained to Indore, and not something that you’re worried about in terms of other facilities? So that’s number one. Number two, on cenerimod and selatogrel, just given your comments on enrollment, can we assume that these are going to be coming in late 2026 in terms of the data? It doesn’t look like earlier data may happen, but I just wanted to get your thoughts there regarding timing of Phase 3. And then just lastly, just given your comments on capital deployment and your past comments and activity on M&A, I guess my question here is going forward, what does Viatris want to be longer term? I mean, do you want to lean more into brands? Are you looking more at returning capital to shareholders and comfortable with the current business mix? Just I guess just a bigger picture question in terms of where you want to take the company, Scott? Thanks.

Thank you, David. I appreciate the questions and good morning. Regarding your first question about security and the status of our facilities, we had three inspections in 2024. We discussed Indore, which received a warning letter and import alert. The inspection at Carole Park in Australia has been concluded without any voluntary issues or warning letters. That matter is now resolved. The third facility is in Nashik, India, where we are still awaiting the classification of the inspection results. Out of our 26 facilities, all are currently in a compliant status with the relevant health authorities. While we are waiting to hear back from Nashik, the situation at Indore is an isolated case within the network. Moving on to capital allocation, our plans remain unchanged. Over the next five years, we aim to allocate 50% to shareholders through dividends and share buybacks, and the other 50% to business development. This will support regional growth, enhance our revenue and EBITDA through accretive transactions, and fund innovative programs for our pipeline. Our priorities may vary yearly, but this year, we are particularly focused on returning capital to shareholders, with plans for aggressive share buybacks amounting to $500 million to $650 million at a minimum, while also seeking accretive business development opportunities to enhance our revenue and EBITDA.

Right. And to Scott’s point, the $1 billion of capital we’ve announced even with that number, we are maintaining strategic flexibility going forward to evaluate all options for our capital that includes additional share buybacks, that includes accretive business development and the ability, to continue to deleverage if we deem if we’d like.

And this is Philippe. With regards to selatogrel and cenerimod. Yes, the data is expected late 2026 for both programs. As I mentioned, enrollment is going very well for both programs. So it could be a bit earlier than that if the trends continue. But right now, we are keeping that late 2026 timing for the data.

And our next question comes from Ash Verma from UBS. Please go ahead with your questions.

Hi, thanks for taking my questions. So I wanted to understand the implications for 2026. So typically these type of warning letters can take a minimum of two years to dissolve. I know you said that Revlimid was already going to go off, but did you have some offsets planned for it already? And then secondly, just with today’s update, I mean, right now the stock is trading 12% to 15% down in pre-market. Why not be more aggressive on the buyback beyond what you’ve guided here? Thanks.

I’m sorry, Ash. Would you let me answer the first question? I got it was a little bit garbled on the second part of your question. I’ll answer that. So the remediation efforts in Indore are, I would say, more than halfway done. We expect to be done as we get to the late spring, early summer. With the remediation at that point, we’ll ask the FDA to come in and reinspect the facility. Relative to lenalidomide, we talked extensively with the FDA and thought we had a really good case to get it on the exempt list because of the critical nature of that particular medicine. We were unable to do so. We looked for alternate sources of lenalidomide and continue to do so. However, lenalidomide is scheduled to hit a secondary patent cliff. I’ll say, or expected to the economics of it are expected to significantly diminish as we get into January of 2026. So from a lenalidomide perspective, this just brought that event up earlier for us, 10 to 12 months earlier. I certainly would have liked to have that capital to deploy as part of our revenue and EBITDA, but it was an event that was going to happen within 10 months to 12 months. We are looking high and low for alternate ways to be able to fill that. At this point, we don’t have any. Can you please repeat your second question?

Yeah. Let me repeat it. So with today’s update, right now, the stock is trading sort of mid-teens down in pre-market. Why not be even more aggressive on the buyback here beyond what you’ve guided?

Yes, thank you, Ash. Great question. I think what we’re trying to say here, our sector leading cash flows give us tremendous flexibility to do a number of different things. We are planning right now to give back between $1 billion and $1.2 billion to shareholders through dividend and for share buybacks. We definitely will evaluate where the share price is and is there an opportunity to be even more aggressive than that. I think we look at that $500 million to $650 million as a minimum for this year, but we will balance that. As Doretta said, we’ll balance that share buyback relative to some business development opportunities, regional accretive deals that can help us build some more revenue and EBITDA. But certainly, in consideration, we will be increasing that share buyback program if the stock remains under pressure.

And our next question comes from Chris Schott from JPMorgan. Please go ahead with your question.

Hi, great. Thanks so much. Just two for me. Maybe first, can you just elaborate on the scope, maybe size and timing of the enterprise review you mentioned on the call? I’m just wondering, is this something that’s part of just ongoing efficiency efforts or something more substantial potentially? And then my second question was on Indore and gross margins. Can you just maybe just walk through a little bit when we think about the year-over-year step down in gross margins? How much of that’s coming from Indore and how much of that’s coming from some other factors that you cited? Thank you.

Yes, good morning, Chris, and thanks for the questions. I’ll take on the first one and then I’ll kick it over to Doretta to talk about the margins. This cost initiative was something that we had in our heads for a little while. If you think about the cadence of the pattern of the company, four years ago there was a merger of two large global companies. And then since then we have divested four major businesses in terms of biosimilars, women’s healthcare, OTC, and API business. And given all that, I think it’s really good timing. And then with the Indore situation coming this year, I think it is a really good time for us to take a look at the enterprise. Do we have the right cost structure? Do we have the right people in the right places? And not only from a cost efficiency standpoint, but also are we fit for purpose for being able to deliver our goals in 2025, 2026, and beyond? So I think it’s a perfect moment for us to really take a look at our structure, how we are organized, where our resources are allocated, and make sure that we are organized best for today and for the future.

And to your question, Chris, around gross margin, there were a couple of components, as I mentioned, that we are factoring into the step down. The largest component is Indore, just given the high margin nature of both the penalties, as well as lenalidomide, the margin impact of Indore is about close to 80% margin. And then in addition to that, we just have normal kind of base business price erosion and increase in some product supply costs. And that has been offset with kind of benefits from just ongoing segment mix in our business.

And just to follow up on your first question, I think I missed the part around timing and we have already initiated discussions internally around this. We are bringing some external people in to help with this. This will be an exercise that really will be focused on the first half of this year. I think the effect or the positive effect from a cost benefit perspective will most likely be more fully realized in 2026, but it’s something that we have already initiated.

Our next question comes from Jason Gerberry from Bank of America. Please go ahead with your questions.

Hey, guys. Thanks for taking my questions. So just for me, maybe I missed this, but why does the Indore facility issues have an impact on revenues outside the United States? And then my second question, just thinking about your generic pipeline assumptions for 2025, what are you thinking in terms of A, and I know this isn’t like a new product issue, but like is generic Symbicort a headwind in 2025, due to competition? And how would you frame maybe the risk profile in aggregate of the pipeline contribution this year versus last year’s pipeline contribution? Thanks.

So just on the first question, I think when you get a situation like Indore Warning Letter and an active remediation that’s ongoing right now, that active remediation sometimes can cause you to have pause in manufacturing supply issues in certain cases, even though the product can go into Europe, there might be shortages of certain products, as we work through that plan and remediate. We look for alternate sources of products while we are doing the remediation. So you can see some shortages with some products, but certainly not across the board, and it is very specific to product and location. But it has to do with the remediation of the facility. And again, we’ve got a network of facilities here from a manufacturing perspective, 26 globally, and we look for alternate sources when we have a shutdown for remediation or a slowdown for remediation like we do at Indore.

Why don’t I cover to your question around new product revenue, Chris, kind of our confidence in the $450 million to $550 million. We do think this is a derisked number. We’re confident in our range. Our history shows that we have consistently delivered or even exceeded our range. Just to give you a flavor of a little bit of the components, about 20% of that new product range we estimate is from already approved products. And in addition to that, we have several complex products, one of which glucagon was already approved and is in the process of being launched. So obviously, this is a diverse portfolio. There are pushes and takes, but we have confidence in that range.

And on your question specifically, this is Corinne. On your question specifically on generic Symbicort, so Breyna, I want to mention that we are very pleased with the performance of Breyna. And we continue to believe that Breyna will be a key contributor to our revenues and to our complex generics portfolio in 2025. So this is our assumption going forward.

Our next question comes from Umer Raffat from Evercore. Please go ahead with your question.

Hi guys. Thanks for squeezing me in. Two if I may. First, Scott, Doretta for you. At the conference in January, you guys talked about the Indore Warning Letter, you guys mentioned it’s 11 products and four of the 11 were exempt and more could get exempt. So most folks listening in just assume, you know what, hundreds of products in this company, 11 of them, so probably not so much. But the type of EBITDA hit we learned about today, considering also that you knew generic Revlimid was one of them. I’m just curious about the thought process around how you guys communicated that to investors previously? And secondly, on the Idorsia deal, I’m just curious, what’s the new information you’ve learned perhaps on a blinded basis for the ongoing trials, which drove the decision to put in another $100 million, which was technically what Idorsia was going to contribute to the R&D? And I acknowledge they couldn’t get their out-licensing deal done, but just curious about your thought process as well.

Yes. So relative to disclosure, It was a very dynamic situation at that time. There were some products which were excluded, others in which we had agreement from the FDA that we could go ahead and ask for exclusions and put our case together, why. So we were unsure exactly what that would look like. We were also exploring alternate forms of lenalidomide from other companies to help fill that shortage gap. So it was a very dynamic situation at that time. We didn’t even have a good view on exactly whether lenalidomide would be excluded or not until just a few days ago. So it has been very dynamic. We thought we had a great case because of the importance of the medication. It just did not materialize. And so for me to start to say, well, there is this product and not that product without being able to give the whole picture, I think gets to our credibility. What was really concerning to me was to be accurate, to be credible to when I understood what exactly that list would look like and what exactly the impacts would look like that I could share that. And I think it has only been in the last couple of days that it’s been very clear to us what the U.S. and non-U.S. impacts are, including lenalidomide. I think the distortion that you see in terms of the magnitude from a revenue and EBITDA perspective because specifically of lenalidomide and the profit profile of that particular product. Idorsia, Philippe, do you want to just address what the status of those programs and what gives us confidence to continue to invest in them?

Yes, we are pleased with the current situation. We have engaged significantly with key opinion leaders and various principal investigators. The momentum of the studies is quite strong at this stage of development. We have conducted multiple Independent Data Monitoring Committees and safety committees, all blinded to the data, and the feedback so far has been very encouraging. Regarding selatogrel, it is crucial that we are observing patients self-inject within thirty minutes of symptom onset and then take themselves to the hospital after the injection. The study is advancing as we initially intended and designed, which gives us a sense of confidence for the future.

And, Umer, if I can just add to that, I mean, it became apparent to us during the course of 2024 that these were going to be very important programs. The feedback we were getting from sites and others was very, very positive, as Philippe said. Not that we obviously the data is blinded, we haven’t seen any data that would direct us in a way. But just the way that everything was progressing, it felt to us like these programs were getting more important to us rather than less. And given what was going on with our partners, we thought the idea of making sure that we can enhance the data integrity, transfer these programs to our ownership even more quickly, I think was important given the importance of these programs to our future revenue growth. And also at the same time being able to expand our geographic footprint, be able to get cenerimod into important markets for Asia where we’ve got very substantial infrastructure already and increase the long-term economics by reducing sales and regulatory milestones. It just seemed to us like the right time to do it and a very beneficial situation for us at Viatris.

For cenerimod, just briefly, the rate of interferon went high in Japan is extremely high. For SLE, it’s very, very close to 100%. So having access to that population for cenerimod specifically is quite important.

And our next question comes from Balaji Prasad from Barclays. Please go ahead with your question.

Good morning everyone. Thanks for the questions. Two from me. Firstly, curious about the Investor Day. You have your task clear for you in getting Indore cleared, new complex generics launches on track. And some of the key pipeline events seem to be geared for late 2025 or 2026. So what would the focus of the Investor Day be? Is it more of incremental updates or are you envisaging a strategic shift? That is one. Two, probably a minor follow-up on Indore. It’s reassuring so you see that you’re in control. Is there any commitment from the FDA on the timelines for reinspection in terms of service level from the time you tell them that you’re ready for an inspection? Thank you.

So that one first. It’s difficult to predict the FDA during times of certainty and during times of uncertainty, maybe a little bit even more difficult. Our base plan calls for the remediation to be finished in the next couple of months for us to request over the summer. And hopefully, we can get a reinspection by the end of this year or early into 2026. That’s our baseline timelines that we’re looking at. Definitely contingent upon what happens within the federal government. And I don’t know if there’s going to be changes to the cadence and flow and resources put behind those sorts of inspections, but that’s the base case that we’re going with. In terms of our investor event for later this year, I think there are three main things that we really like to focus on. What does our long-term revenue, EBITDA, and EPS outlook look like? This is a year in 2025, certainly an unexpected challenge in terms of what we have in Indore and moving up the loss of real economics on lenalidomide, but it sets us up to be able to do the hard work this year to grow in 2026 and beyond. And so we want to be able to show that picture, talk about the revenue, EBITDA, and EPS projection that we see over the next five years. We want to talk about the pipeline, both the innovative pipeline and what’s happening, where we are progressing, what are the enrollment rates look like, the base business pipeline and what’s in there and how that’s coming, and the complex generics. There are a lot of important things. I’d like to talk about a comprehensive GLP-1 strategy that we’re going to execute and implement globally. And finally, we’ll be in a good position to really in a few months to talk to you about this enterprise-wide cost initiative that we are entering into and what we see the benefits of that. And not final numbers likely, but certainly we can give a very good progress update on where we are with that.

And just to clarify a point, all the Phase 3 readouts for this year will occur in the first half of this year. So we should be able to share most of that data with you during the Investor Day.

And ladies and gentlemen, with that, we’ll be concluding today’s question-and-answer session. I’d like to turn the floor back over to Scott Smith, CEO, for closing remarks.

Thank you very much and thank you for everybody on the call. Obviously, a little bit of a difficult situation, one that we take very seriously. We have our arms around the situation at Indore, significant impact here on 2025. But the base business is strong. As Doretta mentioned earlier, we would have 3% growth in top-line, 2% growth in EBITDA if it wasn’t for the Indore situation. Again, we take it seriously. We’re working hard on it. But I’m very, very excited about the future. As we head into 2025, we’re focused on driving strong commercial execution. We’re advancing not only the base pipeline but our innovative pipeline as well. We’re prioritizing capital return in 2025 with a focus on share repurchases. We are executing our remediation plans for Indore and we are beginning an enterprise-wide initiative to review our global infrastructure and identify even more additional cost savings. We are very, very committed to doing the hard work in 2025 to drive sustainable growth in 2026 and beyond and look forward to talking about all this and more and giving an update on Indore and everything else as we get to our Investor Day a little bit later this year. So thank you again for your attention.

And ladies and gentlemen, with that, we’ll conclude today’s conference call and presentation. We do thank you for joining. You may now disconnect your lines.